Hepatorenal Syndrome: A Way for Early and Accurate Diagnosis

Mohammad A. Aboul-Ezz; Ali Abdel Rahim; Ahmed El-Mikkawy; Mohammad A. Elkady; Mohamed. A Elrefaiy; Samia El-Shishtawy; Osama  Mosbah; Khaled Mabrouk; Mostafa Elshafie; Omar M. Sabry

doi:10.3889/oamjms.2022.9675

Authors

Mohammad A. Aboul-Ezz Department of Hepato-Gastroenterology
Ali Abdel Rahim Department of Hepato-Gastroenterology, Theodor Bilharz Research Institute, Giza, Egypt
Ahmed El-Mikkawy Department of Hepato-Gastroenterology, Theodor Bilharz Research Institute, Giza, Egypt
Mohammad A. Elkady Department of Hepato-Gastroenterology, Theodor Bilharz Research Institute, Giza, Egypt
Mohamed. A Elrefaiy Department of Hepato-Gastroenterology, Theodor Bilharz Research Institute, Giza, Egypt
Samia El-Shishtawy Department of Nephrology, Theodor Bilharz Research Institute, Giza, Egypt
Osama Mosbah Department of Nephrology, Theodor Bilharz Research Institute, Giza, Egypt
Khaled Mabrouk Department of Clinical Chemistry, Theodor Bilharz Research Institute, Giza, Egypt
Mostafa Elshafie Department of Radiology, Theodor Bilharz Research Institute, Giza, Egypt
Omar M. Sabry Department of Hematology, Theodor Bilharz Research Institute, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2022.9675

Keywords:

Hepatorenal syndrome, Acute kidney injury, Liver cirrhosis

Abstract

BACKGROUND: Hepatorenal syndrome (HRS) is a devastating consequence of liver cirrhosis that is clinically categorized into two subtypes. Acute malfunction of renal role, as measured by an elevation in blood creatinine, significantly underestimates the loss in renal function in cirrhotic individuals; more accurate biomarkers are desperately required in cirrhotic patients.

AIM: The present study set out to uncover new biomarkers for the early prediction of AKI in cirrhotic cases. A comprehensive panel of biomarkers was investigated to get a clear insight into the pathogenesis of HRS.

PATIENTS AND METHODS: Participants in this study were 70 individuals from the hepatogastroenterology unit of the Theodor Bilharz Research Institute (TBRI). Detailed medical data and a physical examination were recorded. Three groups of patients have been identified; Group 1: 30 cases with compensated liver cirrhosis and normal kidney functions. Group 2: 20 cases with decompensated liver cirrhosis and normal kidney functions. Group 3: 20 cases with decompensated liver cirrhosis proved hepatorenal syndrome Type 2 h. The following biomarkers were detected in serum using the sandwich-ELISA method: Human L-arginine ELISA kit, human neutrophil gelatinase related lipocalin (NGAL), human noradrenaline (NA), human asymmetrical dimethylarginine (ADMA), human symmetric dimethylarginine (SDMA), human nitric oxide (NO), and human renin.

RESULTS: There was a highly significant difference between Groups 1 and 2 in NITRIC and ADMA. Significant differences between Groups 2 and 3 in NGAL, noradrenalin, and SDMA were observed. There was a significant difference (Group 2 vs. Group 3) in renin, NITRIC, ADMA, and L-ARGININE. There was highly significant differentiation (Group 2 vs. Group 3) in NGAL, noradrenalin, and SDMA. There was highly significant variation as per odd ratio and confidence interval between (Group 3 vs. Group 2) in NGAL.

CONCLUSION: Assessment of renal biomarkers in individuals with decompensated cirrhosis gives critical information on the etiology of AKI. Further, it may aid in the diagnosis and prognosis of AKI. Renin, NITRIC, ADMA, and L-ARGININE could be used as biomarkers to indicate HRS in individuals with advanced cirrhosis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Appenrodt B, Lammert F. Renal failure in oatients with cirrhosis: Novel classifications, biomarkers, treatment. Visc Med. 2018;34(4):246-52. https://doi.org/10.1159/000492587 PMid:30345281 DOI: https://doi.org/10.1159/000492587

Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16(2):162-77.e1. https://doi.org/10.1016/j.cgh.2017.05.041 PMid:28602971 DOI: https://doi.org/10.1016/j.cgh.2017.05.041

Simonetto DA, Gines P, Kamath SK. Hepatorenal syndrome: Pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. https://doi.org/10.1136/bmj.m2687 PMid:32928750 DOI: https://doi.org/10.1136/bmj.m2687

Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the international club of ascites. Gut. 2015;64:(4):531-7. https://doi.org/10.1136/gutjnl-2014-308874 PMid:25631669 DOI: https://doi.org/10.1136/gutjnl-2014-308874

Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol. 2010;56(7):539-49. https://doi.org/10.1016/j.jacc.2009.12.075 PMid:20688208 DOI: https://doi.org/10.1016/j.jacc.2009.12.075

Härmälä S, Parisinos C, Ryan J, O’Brien A. Effectiveness of intravenous albumin therapy to prevent spontaneous bacterial peritonitis, renal dysfunction and death in adults with cirrhosis: A protocol for a systematic review. BMJ Open. 2019;9(1):e025664. https://doi.org/10.1136/bmjopen-2018-025664 PMid:30700489 DOI: https://doi.org/10.1136/bmjopen-2018-025664

Alsebaey A, Rewisha E, Waked I. Paracentesis-induced circulatory dysfunction: Are there albumin altervatives? Egypt Liver J. 2020;10:39. https://doi.org/10.1186/s43066-020-00047-7 DOI: https://doi.org/10.1186/s43066-020-00047-7

Bräsen JH, Mederacke YS, Schmitz J, Diahovets K, Khalifa A, Hartleben B, et al. Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology. 2019;69(5):2107-19. https://doi.org/10.1002/hep.30499 PMid:30633816 DOI: https://doi.org/10.1002/hep.30499

Sujan R, Cruz-Lemini M, Altamirano J, Simonetto DA, Maiwall R, Axley P, et al. A validated score predicts acute kidney injury and survival in patients with alcoholic hepatitis. Liver Transpl. 2018;24(12):1655-64. https://doi.org/10.1002/lt.25328 PMid:30153377 DOI: https://doi.org/10.1002/lt.25328

Allegretti AS, Solà E, Ginès P. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis. 2020;76(5):710-9. https://doi.org/10.1053/j.ajkd.2020.03.016 PMid:32622560 DOI: https://doi.org/10.1053/j.ajkd.2020.03.016

Huelin P, Solà E, Elia C, Solé C, Risso A, Moreir R, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study. Hepatology. 2019;70(1):319-33. https://doi.org/10.1002/hep.30592 PMid:30810244 DOI: https://doi.org/10.1002/hep.30592

Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131-7. https://doi.org/10.1136/gutjnl-2011-301255 PMid:22637695 DOI: https://doi.org/10.1136/gutjnl-2011-301255

Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, et al. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis. 2017;49(2):202-6. https://doi.org/10.1016/j.dld.2016.11.001 PMid:27876501 DOI: https://doi.org/10.1016/j.dld.2016.11.001

Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study. Clin Transl Gastroenterol. 2021;12(5):e00359. https://doi.org/10.14309/ctg.0000000000000359 PMid:33979307 DOI: https://doi.org/10.14309/ctg.0000000000000359

Mahmoud WA, Abdelkader NA, Mansor A. Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis? Indian J Gastroenterol. 2014;33(3):274-80. https://doi.org/10.1007/s12664-013-0427-x PMid:24287875 DOI: https://doi.org/10.1007/s12664-013-0427-x

Dragicevic M,Košuta I, Kruezi E, Lovrenčić MV, Mrzljak A. Association of asymmetric dimethylarginine and nitric oxide with cardiovascular risk in patients with end-stage liver disease. Medicina. 2020;56(11):622. https://doi.org/10.3390/medicina56110622 PMid:33218157 DOI: https://doi.org/10.3390/medicina56110622

Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol. 2013;19(11):1707-17. https://doi.org/10.3748/wjg.v19.i11.1707 PMid:23555159 DOI: https://doi.org/10.3748/wjg.v19.i11.1707

Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut. 2006;55(4):542-6. https://doi.org/10.1136/gut.2005.076562 PMid:16299035 DOI: https://doi.org/10.1136/gut.2005.076562

Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood). 2006;231(1):70-5. https://doi.org/10.1177/153537020623100108 PMid:16380646 DOI: https://doi.org/10.1177/153537020623100108

Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol. 2012;3:29. https://doi.org/10.3389/fphys.2012.00029 PMid:22363298 DOI: https://doi.org/10.3389/fphys.2012.00029

Harper D, Chandler B. Splanchnic circulation. BJA Educ. 2016;16(2):66-71. https://doi.org/10.1093/bjaceaccp/mkv017 DOI: https://doi.org/10.1093/bjaceaccp/mkv017

Estrela HF, Damásio ES, Fonseca EK, Bergamaschi CT, Campos RR. Differential sympathetic vasomotor activation induced by liver cirrhosis in rats. PLoS One. 2016;11(4):e0152512. https://doi.org/10.1371/journal.pone.0152512 PMid:27055088 DOI: https://doi.org/10.1371/journal.pone.0152512

Mura VL, Pascoli MD. Renin angiotensin aldosterone system in cirrhosis: There is room to try. Dig Liver Dis. 2019;51(2):297-8. https://doi.org/10.1016/j.dld.2018.07.038 PMid:30220630 DOI: https://doi.org/10.1016/j.dld.2018.07.038

Mousa N, Soliman R, Elgamal H, El-Eraky A, Awad M. Hepatorenal syndrome: Update on pathogenesis and management. Med J Viral Hepat. 2018;2(2):7-14. https://doi.org/10.21608/MJVH.2018.55735 DOI: https://doi.org/10.21608/mjvh.2018.55735

Demırtas S, Can M, Yarpuzlu A. Hepatorenal syndrome. J Lab Med. 2006;30(5):272-9. https://doi.org/10.1515/JLM.2006.998 DOI: https://doi.org/10.1515/JLM.2006.998

Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282(2):879-87. https://doi.org/10.1074/jbc.M603606200 PMid:17082183 DOI: https://doi.org/10.1074/jbc.M603606200

Mookerjee RP, Vairappan B, Jalan R. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? Hepatology. 2007;46(3):943-6. https://doi.org/10.1002/hep.21905 PMid:17879360 DOI: https://doi.org/10.1002/hep.21905

Siroen MP, Wiest R, Richir MC, Teerlink T, Rauwerda JA, Drescher FT, et al. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol. 2008;14(47):7214-9. https://doi.org/10.3748/wjg.14.7214 PMid:19084936 DOI: https://doi.org/10.3748/wjg.14.7214

Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAHADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60(6):461-5. https://doi.org/10.1016/j.phrs.2009.07.016 PMid:19682581 DOI: https://doi.org/10.1016/j.phrs.2009.07.016

Ueda S, Yamagishi S, Matsumoto Y, Kaida Y, Fujimi-Hayashida A, Koike K, et al. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD). Life Sci. 2009;84(23-24):853-6. https://doi.org/10.1016/j.lfs.2009.03.018 PMid:19351540 DOI: https://doi.org/10.1016/j.lfs.2009.03.018

Richir MC, Bouwman RH, Teerlink T, Siroen MP, De Vries TP, Van Leeuwen PA. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008;32(6):613-21. https://doi.org/10.1177/0148607108321702 PMid:18974239 DOI: https://doi.org/10.1177/0148607108321702